US English Female Pediatrics 5 saat önce 2 Views The most important challenge facing pediatric rheumatology is a lack of pediatric rheuma...
Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America.
- Citation data:
Pediatric rheumatology online journal, ISSN: 1546-0096, Vol: 15, Issue: 1, Page: 50
- Publication Year:
- Most Recent Tweet View All Tweets
- Most Recent News Mention
The prognosis of children with juvenile dermatomyositis (JDM) has improved remarkably since the 1960's with the use of corticosteroid and immunosuppressive therapy. Yet there remain a minority of children who have refractory disease. Since 2003 the sporadic use of biologics (genetically-engineered proteins that usually are derived from human genes) for inflammatory myositis has been reported. In 2011-2016 we investigated our collective experience of biologics in JDM through the Childhood Arthritis and Rheumatology Research Alliance (CARRA).